Lymphatic and vascular invasion in oral squamous cell carcinoma: Implications for recurrence and survival in a population-based cohort study.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
12 2020
Historique:
received: 20 05 2020
revised: 04 08 2020
accepted: 09 09 2020
pubmed: 9 10 2020
medline: 18 9 2021
entrez: 8 10 2020
Statut: ppublish

Résumé

Numerous studies analyzed lymphovascular invasion (LVI) in various malignant diseases, however, little is known about the role of lymphatic invasion (LI) as well as vascular invasion (VI) in oral squamous cell carcinoma (OSCC). The aim of this study is to illuminate the role of LI and VI in a population-based cohort study. We retrospectively analyzed 745 primarily resected OSCC patients in Eastern Bavaria for histopathologically verified LI and VI. Overall survival (OS) and recurrence-free survival (RFS) were calculated, whereas analysis was performed by uni- and multivariate statistics. Mean follow-up time was 7.4 years. LI was found in 115 patients (15.4%), VI was diagnosed in 23 cases (3.1%). LI correlated significantly with distinct anatomical sites (p = 0.004), increasing pT-classification (p < 0.001), lymph node involvement (p < 0.001), higher grading (p < 0.001), advanced UICC-stages (p < 0.001) and adjuvant therapies (p < 0.001). Similar results were found for VI. Survival analysis resulted in a significantly decreased five-year OS and RFS in patients with diagnosed LI (OS: 41.1%, RFS: 38.3%) in contrast to LI-negative cases (OS: 66.8%, RFS: 59.7.7%, p < 0.001). Analogous outcomes were seen for patients with VI. Additionally, LI was identified as a predictive parameter, indicating individual patients' response to adjuvant therapies. This population-based cohort study underlines the unfavorable aspect of LI and VI on outcome in OSCC. Including LI and VI in existing staging systems could help to stratify patients' risk for adverse outcome and consecutively determine adjuvant treatment in malignant disease.

Identifiants

pubmed: 33032181
pii: S1368-8375(20)30445-0
doi: 10.1016/j.oraloncology.2020.105009
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

105009

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Steffen Spoerl (S)

Department of Cranio-Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.

Michael Gerken (M)

Tumor Center - Institute for Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany.

René Fischer (R)

Department of Otorhinolaryngology, University Hospital Regensburg, Regensburg, Germany.

Andreas Mamilos (A)

Institute of Pathology, University Regensburg, Regensburg, Germany.

Silvia Spoerl (S)

Department of Internal Medicine 5 - Hematology/Oncology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.

Stefanie Wolf (S)

Department of Otorhinolaryngology, St. Elisabeth Hospital Straubing, Straubing, Germany.

Fabian Pohl (F)

Department of Radiation Oncology, University Hospital Regensburg, Regensburg, Germany.

Christoph Klingelhöffer (C)

Department of Cranio-Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.

Tobias Ettl (T)

Department of Cranio-Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.

Torsten E Reichert (TE)

Department of Cranio-Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.

Gerrit Spanier (G)

Department of Cranio-Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany. Electronic address: gerrit.spanier@ukr.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH